These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 22127456)

  • 1. Blanket disapproval of all unlicensed indications is wrong.
    Evans SJ
    BMJ; 2011 Nov; 343():d7726. PubMed ID: 22127456
    [No Abstract]   [Full Text] [Related]  

  • 2. Prescribing bevacizumab off-label contravenes GMC advice.
    Kyle G
    BMJ; 2011 Nov; 343():d7131. PubMed ID: 22077076
    [No Abstract]   [Full Text] [Related]  

  • 3. Cost comparison of ranibizumab and bevacizumab.
    Jackson TL; Kirkpatrick L
    BMJ; 2011 Aug; 343():d5058. PubMed ID: 21862536
    [No Abstract]   [Full Text] [Related]  

  • 4. Avastin is as effective as Lucentis in treating wet age related macular degeneration, study finds.
    Torjesen I
    BMJ; 2013 Jul; 347():f4678. PubMed ID: 23881948
    [No Abstract]   [Full Text] [Related]  

  • 5. Why have UK doctors been deterred from prescribing Avastin?
    Cohen D
    BMJ; 2015 Apr; 350():h1654. PubMed ID: 25834024
    [No Abstract]   [Full Text] [Related]  

  • 6. A licence to cure.
    Aronson JK; Ferner RE
    BMJ; 2015 Apr; 350():h1723. PubMed ID: 25834026
    [No Abstract]   [Full Text] [Related]  

  • 7. Primary care trusts reverse advice to ophthalmologists to use cheaper drug for wet age related macular degeneration.
    Hawkes N
    BMJ; 2012 Jul; 345():e5161. PubMed ID: 22846417
    [No Abstract]   [Full Text] [Related]  

  • 8. Attacks on publicly funded trials: what happens when industry does not want to know the answer.
    Cohen D
    BMJ; 2015 Apr; 350():h1701. PubMed ID: 25834025
    [No Abstract]   [Full Text] [Related]  

  • 9. By the way, doctor. My 78-year-old husband has wet macular degeneration. He is being treated with a drug called Avastin. Is that a good choice?
    Heier JS
    Harv Health Lett; 2010 May; 35(7):6. PubMed ID: 20583361
    [No Abstract]   [Full Text] [Related]  

  • 10. Cheaper alternative for macular degeneration is as safe as licensed drug, review finds.
    Kmietowicz Z
    BMJ; 2014 Sep; 349():g5618. PubMed ID: 25224545
    [No Abstract]   [Full Text] [Related]  

  • 11. Provider, patient and public benefits from a NICE appraisal of bevacizumab (Avastin).
    Rhodes C; Harris J; Sulston J; Spanswick C
    J Med Ethics; 2012 Mar; 38(3):187-9. PubMed ID: 21947806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novartis takes legal action over trusts' advice to use bevacizumab for wet AMD.
    Torjesen I
    BMJ; 2012 Apr; 344():e2959. PubMed ID: 22532011
    [No Abstract]   [Full Text] [Related]  

  • 13. Legal. PCTs taken to court over use of cheaper drug.
    Calkin S
    Health Serv J; 2012 Apr; 122(6303):10-1. PubMed ID: 22741353
    [No Abstract]   [Full Text] [Related]  

  • 14. Age-related macular degeneration, anti-VEGF therapy, and ophthalmic imaging: is there a best practice?
    Han DP
    JAMA Ophthalmol; 2013 Sep; 131(9):1124-6. PubMed ID: 23744293
    [No Abstract]   [Full Text] [Related]  

  • 15. Cost comparison of intravitreal aflibercept with bevacizumab and ranibizumab for the treatment of wet age-related macular degeneration.
    Shaikh AH; Toussaint BW; Miller DM; Petersen MR; Foster RE; Riemann CD; Hutchins RK; Sisk RA
    Ophthalmic Surg Lasers Imaging Retina; 2015 Jan; 46(1):62-6. PubMed ID: 25559511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bevacizumab for neovascular age-related macular degeneration using a treat-and-extend regimen: clinical and economic impact.
    Shienbaum G; Gupta OP; Fecarotta C; Patel AH; Kaiser RS; Regillo CD
    Am J Ophthalmol; 2012 Mar; 153(3):468-473.e1. PubMed ID: 21996309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New treatments for age-related macular degeneration.
    Taylor HR; Pezzullo ML; Guymer R
    Lancet; 2007 Oct; 370(9597):1481. PubMed ID: 17964346
    [No Abstract]   [Full Text] [Related]  

  • 18. I've heard that new medications to treat wet age-related macular degeneration (AMD) are available. Are these new medications better than current treatments?
    Johns Hopkins Med Lett Health After 50; 2006 Dec; 18(10):8. PubMed ID: 17290531
    [No Abstract]   [Full Text] [Related]  

  • 19. The price of sight--ranibizumab, bevacizumab, and the treatment of macular degeneration.
    Steinbrook R
    N Engl J Med; 2006 Oct; 355(14):1409-12. PubMed ID: 17021315
    [No Abstract]   [Full Text] [Related]  

  • 20. Age-related macular degeneration: treatment at what cost?
    The Lancet
    Lancet; 2018 Sep; 392(10153):1090. PubMed ID: 30303068
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.